TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
last updated:
12 December, 2024
The value of Chinese biotech development deals, mostly out-licensing, rose 68 per cent year on year in the first nine months of last year to US$36.6 billion. Photo: Shutterstock
China Future Tech briefing

Chinese biotech firms cash in on promising drug discoveries via licensing

China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.

videocam
Artificial intelligence

AI-driven firm aims to transform drug discovery

Artificial intelligence

AI-driven drug discovery aided by Greater Bay Area integration, firm says

videocam
Biomedicine: Science

CR Pharma, NAMI join forces to fight Alzheimer’s with Pfizer cancer drug

Palbociclib, developed by Pfizer for certain types of advanced breast cancer, was approved for sale in 2015.

Hong Kong’s Nano and Advanced Materials Institute. Photo: innovationhub.hk
US-China relations

China’s WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.

New medical drugs

Novel drug awaits Hong Kong diabetics suffering from debilitating eye disease

Oculis’ OCS-01 eye drops, currently in phase 3 trials for diabetic macular edema, can be an alternative to injection, CEO says.

videocam
Advertisement
Advertisement
Advertisement
Wuxi AppTec

WuXi AppTec, WuXi Biologics surge on slimmer chances of Biosecure Act’s passage

The bill’s absence from the proposed amendments to the US National Defence Authorisation Act comes as a reprieve for the two biotech firms.

WuXi AppTec says it provides US lawmakers and federal agencies with information about the services it provides to customers in the US and around the world. Photo: Shutterstock
Biomedicine: Science

Hong Kong residents reticent to get latest Covid-19 jab, Moderna survey finds

About 52 per cent of Hong Kong respondents said they were willing to get the updated vaccine, compared with 58 per cent in Singapore.

Biomedicine: Industry Trends

China welcomes new US$1 billion Sanofi project in Beijing

Sanofi’s latest capital outlay in China will cover the development of a new insulin plant in the nation’s capital.

Biomedicine: Science

Hong Kong start-up eyes global pest control market with scent-based products

Plasticvore is a two-year old biotech start-up offering alternative, humane solutions to controlling and eliminating pests, founder says.

videocam
Plasticvore is eyeing orders from the US, Europe and Southeast Asia, founder Rick Lui says. Photo: Edmond So
Health & Fitness

China expands health insurance coverage with 91 new drugs, innovative treatments

The health authority shows its support for novel drugs, while driving tough bargains with pharmaceutical firms on prices.

videocam
China has added dozens of new drugs to its medical insurance reimbursement list. Photo: Getty Images
SCMP Highlights

Recap | ‘Promising’ steps to HIV vaccine, Trump tariffs threaten profits: 5 biotech stories

Discover breakthroughs in the biotech world, from a potential HIV cure to China’s booming drug market and innovative coronavirus treatments, in some of our latest stories.

Biomedicine: Geopolitics

Chinese biotech firms brace for Trump tariffs, US funding bill

Efforts to expand sales of high-value products in China and non-US markets would cushion the blow, analysts say.

Hong Kong

Vaccine shows promise in curing HIV, Hong Kong start-up says

‘We may be on the brink of a breakthrough,’ Dr Edward Leong, advisory board chairman of Immuno Cure says.

A Hong Kong biotech start-up says its first-phase trial of a therapeutic HIV vaccine has shown promising results. Photo: dpa
Biomedicine: Science

Germany’s BioNTech buys Biotheus in US$800 million push into cancer drugs

BioNTech says deal will support its push into the development of cancer drugs using its proven mRNA technology.

Ugur Sahin, CEO and co-founder of BioNTech. Photo: Reuters
Science

Opinion | Why a new approach to diabetes treatment is desperately needed

Current widely used treatment approaches are not fit for task as they ignore the idiosyncrasies in diabetes that can arise in each patient.

videocam
Health in China

Chinese pharmaceutical companies look abroad for growth markets

Shanghai Henlius struck a deal in Saudi Arabia while XtalPi signed a partnership with Sinar Mas Multiartha in Indonesia.

Advertisement
Advertisement
Advertisement
Greater Bay Area

Hong Kong health-tech start-ups create digital wearables for seniors

With a regulatory approach that expands the market for such devices to the Greater Bay Area, local companies see opportunity for growth.

videocam
Senior Hongkongers exercise at Victoria Park in Causeway Bay. Photo: Dickson Lee
Coronavirus vaccine

AstraZeneca’s China president under ‘ongoing investigation’: company

Drug maker has yet to elaborate whether Leon Wang is in custody, nor have his whereabouts been disclosed.

FII conference

Hong Kong start-ups eye Middle East capital under new accord with venture fund

Start-ups with expertise in artificial intelligence, biotech and green energy can contribute to Saudi Arabia’s economic diversification agenda.

5
Biomedicine: Industry Trends

Hong Kong health tech: private-public alliance advances male HPV testing

Neo-Health Group says its device, developed with a government-backed research institute, will also help test for skin infections and cancers.

The Nanoswab device viewed through an optical microscope. Photo: Handout
Cancer

CK Life’s Yuen banks on Big Pharma experience to boost new drug success

Lance Yuen spent two decades at Bristol Myers Squibb and Bayer in the region before becoming the CEO at CK Life Sciences last month.

CK Life Sciences management (from left) Wendy Tong Barnes, chief corporate affairs officer Wendy Tong-Barnes, CEO Lance Yuen, deputy chairman Alan Yu, chief scientific officer Melvin Toh, and vice president corporate development Cecilia Ho
Wuxi AppTec

WuXi AppTec, WuXi Biologics rise in Hong Kong as some operations go up for sale

The gains were made on the back of a report that said the two firms plan to sell certain overseas operations amid heightened US scrutiny.

China stock market

Wuxi AppTec’s upbeat business update boosts stock despite US bill

A presentation persuaded investors that risk of a potential US blacklisting is low while growth in some business areas is ‘unprecedented’.

Health & Fitness

Ultrasound cancer treatment, supported by Li Ka-shing, gains traction in Asia

Focused ultrasound, backed by Li Ka-shing, is emerging as a non-invasive, commercially viable cancer treatment, attracting significant investments.

videocam
Neal Kassell, a neurosurgeon, is the founder and chairman of US-based Focused Ultrasound Foundation. Photo: Sun Yeung
Business of climate change

Hong Kong’s advanced materials institute eyes bay area presence

Non-profit institute sees opportunities in licensing its technology to generate income to fund new equipment and facilities, CEO Fung says.

videocam
‘The priority is to commercialise our technology for local applications,’ NAMI CEO Andy Fung says. Photo: Handout
US-China relations

Opinion | Is biotech the next battleground in US-China decoupling?

With both countries viewing technological leadership as a zero-sum game, the risk of a fragmented global innovation ecosystem is growing.

videocam
Hong Kong stock market

US bill targets Chinese biotechs Wuxi AppTec, Wuxi Biologics

Shares of Wuxi AppTec and Wuxi Biologics fell after the US House passed a bill that would restrict business with Chinese biotech companies.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
loading